Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PvP001
- Development stage
- Unknown
- Lead developer
- Millennium Pharmaceuticals
- Modality
- Peptides, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
PvP001 (TAK-062) is a recombinant, computationally engineered protease developed for the treatment of celiac disease. Originally developed by PvP Bio and later acquired by Takeda, the enzyme (known as KumaMax) is a modified version of kumamolisin-As. It is designed to remain highly active in the acidic environment of the stomach and specifically target and degrade the immunogenic proline- and glutamine-rich peptides of gluten before they reach the small intestine. By breaking down these peptides, PvP001 aims to prevent the inflammatory and autoimmune response triggered by accidental gluten ingestion in patients following a gluten-free diet. PvP001 refers specifically to the liquid formulation used in early clinical trials, while PVP002 and PVP003 represent capsule and tablet formulations, respectively.
- Other names
- PvP001PvP-001PvP 001KumaMaxKuma030Kuma-030Kuma 030
Beyond the preview
Go deeper on PvP001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PvP001.